Sternberger, L. A. & Sternberger, N. H. Monoclonal antibodies distinguish phosphorylated and nonphosphorylated forms of neurofilaments in situ. Proc. Natl Acad. Sci. USA 80, 6126–6130 (1983).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stark, S. E. & Caton, A. J. Antibodies that are specific for a single amino acid interchange in a protein epitope use structurally distinct variable regions. J. Exp. Med. 174, 613–624 (1991).

Article  CAS  PubMed  Google Scholar 

Antibody therapeutics approved or in regulatory review in the EU or US. Antibody Society www.antibodysociety.org/resources/approved-antibodies (2023). The Antibody Society is an association that supports research and development of antibody-based drugs and maintains an updated list of antibodies approved by the FDA and EMA.

June, C. H. & Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med. 379, 64–73 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Labanieh, L. & Mackall, C. L. CAR immune cells: design principles, resistance and the next generation. Nature 614, 635–648 (2023).

Article  CAS  PubMed  Google Scholar 

Carter, P. Improving the efficacy of antibody-based cancer therapies. Nat. Rev. Cancer 1, 118–129 (2001).

Article  CAS  PubMed  Google Scholar 

Weiner, G. J. Building better monoclonal antibody-based therapeutics. Nat. Rev. Cancer 15, 361–370 (2015).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ho, M. Inaugural editorial: searching for magic bullets. Antib. Ther. 1, 1–5 (2018).

CAS  PubMed  PubMed Central  Google Scholar 

Kohler, G. & Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495–497 (1975). This seminal paper describes the hybridoma technology that enabled the production of monoclonal antibodies. Kohler and Milstein received the Nobel Prize for this work.

Article  CAS  PubMed  Google Scholar 

Hwang, W. Y. & Foote, J. Immunogenicity of engineered antibodies. Methods 36, 3–10 (2005).

Article  CAS  PubMed  Google Scholar 

Reff, M. E. et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83, 435–445 (1994). This paper describes the generation of rituximab, the first chimeric antibody that demonstrated significant tumour reduction and later became the standard of care for the treatment of patients with B cell lymphomas.

Article  CAS  PubMed  Google Scholar 

Goldstein, N. I., Prewett, M., Zuklys, K., Rockwell, P. & Mendelsohn, J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res. 1, 1311–1318 (1995).

CAS  PubMed  Google Scholar 

Looney, R. J. et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 50, 2580–2589 (2004).

Article  CAS  PubMed  Google Scholar 

Jones, P. T., Dear, P. H., Foote, J., Neuberger, M. S. & Winter, G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321, 522–525 (1986). This paper describes the process of CDR grafting that enabled the production of humanized antibodies. The majority of cancer antibodies utilize the humanized antibody format.

Article  CAS  PubMed  Google Scholar 

Carter, P. et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl Acad. Sci. USA 89, 4285–4289 (1992).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Spieker-Polet, H., Sethupathi, P., Yam, P. C. & Knight, K. L. Rabbit monoclonal antibodies: generating a fusion partner to produce rabbit-rabbit hybridomas. Proc. Natl Acad. Sci. USA 92, 9348–9352 (1995).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang, Y. F. & Ho, M. Humanization of rabbit monoclonal antibodies via grafting combined Kabat/IMGT/Paratome complementarity-determining regions: rationale and examples. MAbs 9, 419–429 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Parray, H. A. et al. Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives. Int. Immunopharmacol. 85, 106639 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

McCafferty, J., Griffiths, A. D., Winter, G. & Chiswell, D. J. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348, 552–554 (1990). This paper describes the early phage display technologies that enabled the selection of antibodies against a range of antigens including cancer antigens. G. Smith and G. Winter received the Nobel Prize for their work on phage display-based antibody production.

Article  CAS  PubMed  Google Scholar 

Lonberg, N. et al. Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 368, 856–859 (1994). This paper describes the development of transgenic mouse models that led to the production of fully human antibodies.

Article  CAS  PubMed  Google Scholar 

Lu, R. M. et al. Development of therapeutic antibodies for the treatment of diseases. J. Biomed. Sci. 27, 1 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Winter, G., Griffiths, A. D., Hawkins, R. E. & Hoogenboom, H. R. Making antibodies by phage display technology. Annu. Rev. Immunol. 12, 433–455 (1994).

Article  CAS  PubMed  Google Scholar 

Lu, S. et al. The rapid and highly parallel identification of antibodies with defined biological activities by SLISY. Nat. Commun. 14, 17 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alfaleh, M. A. et al. Phage display derived monoclonal antibodies: from bench to bedside. Front. Immunol. 11, 1986 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Almagro, J. C., Daniels-Wells, T. R., Perez-Tapia, S. M. & Penichet, M. L. Progress and challenges in the design and clinical development of antibodies for cancer therapy. Front. Immunol. 8, 1751 (2017).

Article  PubMed  Google Scholar 

Booth, B. Human antibody discovery: of mice and phage. Forbes https://www.forbes.com/sites/brucebooth/2017/05/11/human-antibody-discovery-of-mice-and-phage/?sh=1f76520c7f26 (2017).

Jain, T. et al. Biophysical properties of the clinical-stage antibody landscape. Proc. Natl Acad. Sci. USA 114, 944–949 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Douglass, J. et al. Bispecific antibodies targeting mutant RAS neoantigens. Sci. Immunol. 6, eabd5515 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hsiue, E. H. et al. Targeting a neoantigen derived from a common TP53 mutation. Science 371, eabc8697 (2021). This paper describes the generation of bispecific antibodies targeting the most common oncogenic mutation (R175H) in the tumour suppressor protein p53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Boder, E. T., Midelfort, K. S. & Wittrup, K. D. Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. Proc. Natl Acad. Sci. USA 97, 10701–10705 (2000).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Georgiou, G. et al. Display of heterologous proteins on the surface of microorganisms: from the screening of combinatorial libraries to live recombinant vaccines. Nat. Biotechnol. 15, 29–34 (1997).

Article  CAS  PubMed  Google Scholar 

Ho, M., Nagata, S. & Pastan, I. Isolation of anti-CD22 Fv with high affinity by Fv display on human cells. Proc. Natl Acad. Sci. USA 103, 9637–9642 (2006).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lipovsek, D. & Pluckthun, A. In-vitro protein evolution by ribosome display and mRNA display. J. Immunol. Methods 290, 51–67 (2004).

Article  CAS  PubMed  Google Scholar 

Wang, J. et al. Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit. MAbs 11, 1443–1451 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marcus, R. et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N. Engl. J. Med. 377, 1331–1344 (2017).

Article  CAS  PubMed  Google Scholar 

Vitolo, U. et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. J. Clin. Oncol. 35, 3529–3537 (2017).

Article  CAS  PubMed  Google Scholar 

van Imhoff, G. W. et al. Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the ORCHARRD study. J. Clin. Oncol. 35, 544–551 (2017).

Article  PubMed